BRPI0416925A - biomarcadores para a eficácia de tratamento com análogo de somatostatina - Google Patents
biomarcadores para a eficácia de tratamento com análogo de somatostatinaInfo
- Publication number
- BRPI0416925A BRPI0416925A BRPI0416925-5A BRPI0416925A BRPI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A BR PI0416925 A BRPI0416925 A BR PI0416925A
- Authority
- BR
- Brazil
- Prior art keywords
- pasireotide
- biomarkers
- igf
- somatostatin
- efficacy
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 229940075620 somatostatin analogue Drugs 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229960005415 pasireotide Drugs 0.000 abstract 2
- 108700017947 pasireotide Proteins 0.000 abstract 2
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000003633 gene expression assay Methods 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- -1 somatostatin pasireotide analog Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"BIOMARCADORES PARA A EFICáCIA DE TRATAMENTO COM ANáLOGO DE SOMATOSTATINA". Ensaios de expressão genética foram realizados usando tecidos de macacos tratados com o análogo de somatostatina pasireotide em uma dose subterapêutica por 14 dias. Os ensaios foram analisados para identificar os modos de ações de pasireotide com relação a aplicações terapêuticas. Os efeitos sobre os eixos do hormónio do crescimento /IGF-1 e glucagon /insulina foram refletidos nas alterações do nível de transcrito em vários órgãos. Os genes expressos são úteis como marcadores substituintes da atividade biológica de pasireotide especialmente os achados para IGF-2 na pituitária e rins.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52507903P | 2003-11-25 | 2003-11-25 | |
| PCT/EP2004/013350 WO2005053732A1 (en) | 2003-11-25 | 2004-11-24 | Biomarkers for the efficacy of somatostatin analogue treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416925A true BRPI0416925A (pt) | 2007-01-16 |
Family
ID=34652298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416925-5A BRPI0416925A (pt) | 2003-11-25 | 2004-11-24 | biomarcadores para a eficácia de tratamento com análogo de somatostatina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070275382A1 (pt) |
| EP (1) | EP1689429A1 (pt) |
| JP (1) | JP2007518702A (pt) |
| KR (1) | KR20060118504A (pt) |
| CN (1) | CN1905895A (pt) |
| AU (1) | AU2004294269A1 (pt) |
| BR (1) | BRPI0416925A (pt) |
| CA (1) | CA2546448A1 (pt) |
| IL (1) | IL175574A0 (pt) |
| MX (1) | MXPA06005952A (pt) |
| WO (1) | WO2005053732A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090387A1 (es) | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| US8937152B2 (en) * | 2007-12-03 | 2015-01-20 | Italfarmaco Spa | Non-selective somatostatin analogues |
| WO2010003939A1 (en) | 2008-07-08 | 2010-01-14 | Novartis Ag | Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia |
| WO2013151688A1 (en) * | 2012-04-06 | 2013-10-10 | Georgia Regents University | Methods and compositions for using insulin-like growth factor binding protein 6 in treating and diagnosing diabetes |
| AU2018388549B2 (en) * | 2017-12-18 | 2023-06-01 | Yale University | Compounds and compositions for treating fibrosis |
| CN110144412B (zh) * | 2019-06-10 | 2022-08-19 | 西北农林科技大学 | 一种与南阳牛生长相关的cnv标记的检测方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2216290T3 (es) * | 1997-05-13 | 2004-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x. |
| US5968903A (en) * | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| WO2002092854A2 (en) * | 2001-05-16 | 2002-11-21 | Novartis Ag | Genes expressed in breast cancer as prognostic and therapeutic targets |
| JP2005522221A (ja) * | 2002-04-17 | 2005-07-28 | ノバルティス アクチエンゲゼルシャフト | チロシンキナーゼ阻害剤に対する患者応答性の予測方法 |
-
2004
- 2004-11-24 JP JP2006540373A patent/JP2007518702A/ja active Pending
- 2004-11-24 EP EP04798070A patent/EP1689429A1/en not_active Withdrawn
- 2004-11-24 MX MXPA06005952A patent/MXPA06005952A/es not_active Application Discontinuation
- 2004-11-24 CA CA002546448A patent/CA2546448A1/en not_active Abandoned
- 2004-11-24 WO PCT/EP2004/013350 patent/WO2005053732A1/en not_active Ceased
- 2004-11-24 KR KR1020067010168A patent/KR20060118504A/ko not_active Withdrawn
- 2004-11-24 AU AU2004294269A patent/AU2004294269A1/en not_active Abandoned
- 2004-11-24 BR BRPI0416925-5A patent/BRPI0416925A/pt not_active Application Discontinuation
- 2004-11-24 CN CNA2004800409179A patent/CN1905895A/zh active Pending
- 2004-11-24 US US10/580,778 patent/US20070275382A1/en not_active Abandoned
-
2006
- 2006-05-11 IL IL175574A patent/IL175574A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005053732A1 (en) | 2005-06-16 |
| EP1689429A1 (en) | 2006-08-16 |
| MXPA06005952A (es) | 2006-07-06 |
| KR20060118504A (ko) | 2006-11-23 |
| CA2546448A1 (en) | 2005-06-16 |
| CN1905895A (zh) | 2007-01-31 |
| AU2004294269A1 (en) | 2005-06-16 |
| IL175574A0 (en) | 2006-09-05 |
| US20070275382A1 (en) | 2007-11-29 |
| JP2007518702A (ja) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pigossi et al. | Role of osteogenic growth peptide (OGP) and OGP (10–14) in bone regeneration: a review | |
| Greenhalgh | The role of growth factors in wound healing | |
| Philp et al. | Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development | |
| EP1651676A4 (en) | GLUCAN FOR IMPROVING THERAPY | |
| DE69922933D1 (de) | Anwendungen für humane nicht autologe, mesenchymale stammzellen | |
| Lepistö et al. | Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat | |
| JP2015057431A (ja) | 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 | |
| EP0681475A4 (en) | Therapeutic inhibitors of vascular smooth muscle cells | |
| Hwang et al. | An effective range of polydeoxyribonucleotides is critical for wound healing quality | |
| BRPI0410915A (pt) | composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit | |
| BR9710615A (pt) | Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea. | |
| Kook et al. | COMP-angiopoietin 1 increases proliferation, differentiation, and migration of stem-like cells through Tie-2-mediated activation of p38 MAPK and PI3K/Akt signal transduction pathways | |
| Hirsch et al. | Insulin‐like growth factor‐1 gene therapy and cell transplantation in diabetic wounds | |
| BRPI0416925A (pt) | biomarcadores para a eficácia de tratamento com análogo de somatostatina | |
| US20240252494A1 (en) | Mechanotransduction Disruption Mediation in Skin Grafting Methods and Compositions for Use in Practicing the Same | |
| Nicosia et al. | Mimicking molecular pathways in the design of smart hydrogels for the design of vascularized engineered tissues | |
| Kwon et al. | Regeneration of Chronic Rotator Cuff Tear in a Rabbit Model: Synergetic Benefits of Human Umbilical Cord Blood‐Derived Mesenchymal Stem Cells, Polydeoxyribonucleotides, and Microcurrent Therapy | |
| Brembilla et al. | Adipose-derived stromal cells within a gelatin matrix acquire enhanced regenerative and angiogenic properties: A pre-clinical study for application to chronic wounds | |
| ATE208814T1 (de) | Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere | |
| Wong et al. | Applications, and efficient large-scale production, of recombinant human epidermal growth factor | |
| US20090306219A1 (en) | Topical use of plant extract for skin detoxification | |
| CN102292092A (zh) | 致敏细胞疗法 | |
| Zhang et al. | Mesenchymal Stem Cell Senescence and Biomaterial-Based Next-Generation Rejuvenation Strategy | |
| Xiao et al. | Association of Fpr1 gene expression with osteogenesis and adipogenesis of adipose derived stem cells | |
| RU2392000C1 (ru) | Способ терапии экспериментального хронического токсического гепатита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |